IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors

In this study, we show that IFN-gamma or IFN-alpha reduce expression of H60 on 3'-methylcholanthrene (MCA) sarcomas from 129/Sv mice. As determined by flow cytometry using either NKG2D tetramers or NKG2D ligand-specific mAb, H60 was identified as the NKG2D ligand most frequently expressed on th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Immunology 2006-01, Vol.176 (2), p.905-913
Hauptverfasser: Bui, Jack D, Carayannopoulos, Leonidas N, Lanier, Lewis L, Yokoyama, Wayne M, Schreiber, Robert D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 913
container_issue 2
container_start_page 905
container_title Journal of Immunology
container_volume 176
creator Bui, Jack D
Carayannopoulos, Leonidas N
Lanier, Lewis L
Yokoyama, Wayne M
Schreiber, Robert D
description In this study, we show that IFN-gamma or IFN-alpha reduce expression of H60 on 3'-methylcholanthrene (MCA) sarcomas from 129/Sv mice. As determined by flow cytometry using either NKG2D tetramers or NKG2D ligand-specific mAb, H60 was identified as the NKG2D ligand most frequently expressed on these sarcomas, and its expression was selectively down-regulated by either IFN-gamma or IFN-alpha in a manner that was dose- and time-dependent and reversible. Down-regulation occurred at the transcript level and was STAT1-dependent. It also had functional consequences. IFN-gamma-treated MCA sarcomas with high levels of H60 were resistant to killing by IL-2-activated NK cells. Resistance was not solely dependent on enhanced MHC class I expression but rather also required H60 down-regulation. IFN-gamma-treated tumor cells also displayed diminished capacity to down-regulate NKG2D on freshly isolated NK cells. Transplanted tumor cells reisolated from immunocompetent mice displayed reduced H60 expression and increased MHC class I expression compared with tumor cells that were either left unmanipulated or reisolated from mice treated with neutralizing IFN-gamma-specific mAb. This report thus represents the first demonstration that certain cytokines and specifically the IFNs regulate expression of specific NKG2D ligands on murine tumors. This process most likely helps to specify the type of immune effector cell populations that participate in host-protective antitumor responses.
doi_str_mv 10.4049/jimmunol.176.2.905
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67607735</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67607735</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-e7c0eafdf72d14f2d1b3c2dd9129b9def6835da0321626466aa0d6d29d63c7233</originalsourceid><addsrcrecordid>eNqFkEtPwkAQxzdGI4h-AQ-mJ2_F2Udn2ZMxII9IMDF43izdLZT0gd02jd_eGjAcvcwc_o_J_Ai5pzAUINTTPs3zpiizIZU4ZEMF0QXp0yiCEBHwkvQBGAs7UfbIjfd7AEBg4pr0KHLFlYz65HkxXYUTd3CFdUUdTMq2CD_ctslMnZZFUCZBvXPB6m3GJsEy3ZrCBnOEoJPWTV5W_pZcJSbz7u60B-Rz-roez8Pl-2wxflmGsZC8Dp2MwZnEJpJZKpJubHjMrFWUqY2yLsERj6wBzigyFIjGgEXLlEUeS8b5gDweew9V-dU4X-s89bHLMlO4svEaJYKUPPrXSKVAMereHxB2NMZV6X3lEn2o0txU35qC_uWr__h2GdRMd3y70MOpvdnkzp4jJ6Dn87t0u2vTymmfmyzr7FS3bXtu-gFIboOl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17464839</pqid></control><display><type>article</type><title>IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors</title><source>MEDLINE</source><source>Wiley Free Content</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Bui, Jack D ; Carayannopoulos, Leonidas N ; Lanier, Lewis L ; Yokoyama, Wayne M ; Schreiber, Robert D</creator><creatorcontrib>Bui, Jack D ; Carayannopoulos, Leonidas N ; Lanier, Lewis L ; Yokoyama, Wayne M ; Schreiber, Robert D</creatorcontrib><description>In this study, we show that IFN-gamma or IFN-alpha reduce expression of H60 on 3'-methylcholanthrene (MCA) sarcomas from 129/Sv mice. As determined by flow cytometry using either NKG2D tetramers or NKG2D ligand-specific mAb, H60 was identified as the NKG2D ligand most frequently expressed on these sarcomas, and its expression was selectively down-regulated by either IFN-gamma or IFN-alpha in a manner that was dose- and time-dependent and reversible. Down-regulation occurred at the transcript level and was STAT1-dependent. It also had functional consequences. IFN-gamma-treated MCA sarcomas with high levels of H60 were resistant to killing by IL-2-activated NK cells. Resistance was not solely dependent on enhanced MHC class I expression but rather also required H60 down-regulation. IFN-gamma-treated tumor cells also displayed diminished capacity to down-regulate NKG2D on freshly isolated NK cells. Transplanted tumor cells reisolated from immunocompetent mice displayed reduced H60 expression and increased MHC class I expression compared with tumor cells that were either left unmanipulated or reisolated from mice treated with neutralizing IFN-gamma-specific mAb. This report thus represents the first demonstration that certain cytokines and specifically the IFNs regulate expression of specific NKG2D ligands on murine tumors. This process most likely helps to specify the type of immune effector cell populations that participate in host-protective antitumor responses.</description><identifier>ISSN: 0022-1767</identifier><identifier>EISSN: 1550-6606</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.4049/jimmunol.176.2.905</identifier><identifier>PMID: 16393975</identifier><language>eng</language><publisher>United States: Am Assoc Immnol</publisher><subject>Animals ; Base Sequence ; Cell Line, Tumor ; Cell Proliferation ; Cytotoxicity, Immunologic ; DNA, Complementary - genetics ; DNA, Neoplasm - genetics ; Down-Regulation - drug effects ; Histocompatibility Antigens Class I - metabolism ; Humans ; Interferon Type I - pharmacology ; Interferon-gamma - pharmacology ; Killer Cells, Natural - immunology ; Ligands ; Mice ; Mice, Inbred C57BL ; Minor Histocompatibility Antigens - genetics ; Minor Histocompatibility Antigens - metabolism ; Neoplasm Transplantation ; NK Cell Lectin-Like Receptor Subfamily K ; Receptors, Immunologic - metabolism ; Receptors, Natural Killer Cell ; Recombinant Proteins ; Sarcoma, Experimental - drug therapy ; Sarcoma, Experimental - immunology ; Sarcoma, Experimental - pathology ; STAT1 Transcription Factor - metabolism ; Transplantation, Isogeneic</subject><ispartof>Journal of Immunology, 2006-01, Vol.176 (2), p.905-913</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-e7c0eafdf72d14f2d1b3c2dd9129b9def6835da0321626466aa0d6d29d63c7233</citedby><cites>FETCH-LOGICAL-c473t-e7c0eafdf72d14f2d1b3c2dd9129b9def6835da0321626466aa0d6d29d63c7233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16393975$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bui, Jack D</creatorcontrib><creatorcontrib>Carayannopoulos, Leonidas N</creatorcontrib><creatorcontrib>Lanier, Lewis L</creatorcontrib><creatorcontrib>Yokoyama, Wayne M</creatorcontrib><creatorcontrib>Schreiber, Robert D</creatorcontrib><title>IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors</title><title>Journal of Immunology</title><addtitle>J Immunol</addtitle><description>In this study, we show that IFN-gamma or IFN-alpha reduce expression of H60 on 3'-methylcholanthrene (MCA) sarcomas from 129/Sv mice. As determined by flow cytometry using either NKG2D tetramers or NKG2D ligand-specific mAb, H60 was identified as the NKG2D ligand most frequently expressed on these sarcomas, and its expression was selectively down-regulated by either IFN-gamma or IFN-alpha in a manner that was dose- and time-dependent and reversible. Down-regulation occurred at the transcript level and was STAT1-dependent. It also had functional consequences. IFN-gamma-treated MCA sarcomas with high levels of H60 were resistant to killing by IL-2-activated NK cells. Resistance was not solely dependent on enhanced MHC class I expression but rather also required H60 down-regulation. IFN-gamma-treated tumor cells also displayed diminished capacity to down-regulate NKG2D on freshly isolated NK cells. Transplanted tumor cells reisolated from immunocompetent mice displayed reduced H60 expression and increased MHC class I expression compared with tumor cells that were either left unmanipulated or reisolated from mice treated with neutralizing IFN-gamma-specific mAb. This report thus represents the first demonstration that certain cytokines and specifically the IFNs regulate expression of specific NKG2D ligands on murine tumors. This process most likely helps to specify the type of immune effector cell populations that participate in host-protective antitumor responses.</description><subject>Animals</subject><subject>Base Sequence</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Cytotoxicity, Immunologic</subject><subject>DNA, Complementary - genetics</subject><subject>DNA, Neoplasm - genetics</subject><subject>Down-Regulation - drug effects</subject><subject>Histocompatibility Antigens Class I - metabolism</subject><subject>Humans</subject><subject>Interferon Type I - pharmacology</subject><subject>Interferon-gamma - pharmacology</subject><subject>Killer Cells, Natural - immunology</subject><subject>Ligands</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Minor Histocompatibility Antigens - genetics</subject><subject>Minor Histocompatibility Antigens - metabolism</subject><subject>Neoplasm Transplantation</subject><subject>NK Cell Lectin-Like Receptor Subfamily K</subject><subject>Receptors, Immunologic - metabolism</subject><subject>Receptors, Natural Killer Cell</subject><subject>Recombinant Proteins</subject><subject>Sarcoma, Experimental - drug therapy</subject><subject>Sarcoma, Experimental - immunology</subject><subject>Sarcoma, Experimental - pathology</subject><subject>STAT1 Transcription Factor - metabolism</subject><subject>Transplantation, Isogeneic</subject><issn>0022-1767</issn><issn>1550-6606</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtPwkAQxzdGI4h-AQ-mJ2_F2Udn2ZMxII9IMDF43izdLZT0gd02jd_eGjAcvcwc_o_J_Ai5pzAUINTTPs3zpiizIZU4ZEMF0QXp0yiCEBHwkvQBGAs7UfbIjfd7AEBg4pr0KHLFlYz65HkxXYUTd3CFdUUdTMq2CD_ctslMnZZFUCZBvXPB6m3GJsEy3ZrCBnOEoJPWTV5W_pZcJSbz7u60B-Rz-roez8Pl-2wxflmGsZC8Dp2MwZnEJpJZKpJubHjMrFWUqY2yLsERj6wBzigyFIjGgEXLlEUeS8b5gDweew9V-dU4X-s89bHLMlO4svEaJYKUPPrXSKVAMereHxB2NMZV6X3lEn2o0txU35qC_uWr__h2GdRMd3y70MOpvdnkzp4jJ6Dn87t0u2vTymmfmyzr7FS3bXtu-gFIboOl</recordid><startdate>20060115</startdate><enddate>20060115</enddate><creator>Bui, Jack D</creator><creator>Carayannopoulos, Leonidas N</creator><creator>Lanier, Lewis L</creator><creator>Yokoyama, Wayne M</creator><creator>Schreiber, Robert D</creator><general>Am Assoc Immnol</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20060115</creationdate><title>IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors</title><author>Bui, Jack D ; Carayannopoulos, Leonidas N ; Lanier, Lewis L ; Yokoyama, Wayne M ; Schreiber, Robert D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-e7c0eafdf72d14f2d1b3c2dd9129b9def6835da0321626466aa0d6d29d63c7233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Base Sequence</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Cytotoxicity, Immunologic</topic><topic>DNA, Complementary - genetics</topic><topic>DNA, Neoplasm - genetics</topic><topic>Down-Regulation - drug effects</topic><topic>Histocompatibility Antigens Class I - metabolism</topic><topic>Humans</topic><topic>Interferon Type I - pharmacology</topic><topic>Interferon-gamma - pharmacology</topic><topic>Killer Cells, Natural - immunology</topic><topic>Ligands</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Minor Histocompatibility Antigens - genetics</topic><topic>Minor Histocompatibility Antigens - metabolism</topic><topic>Neoplasm Transplantation</topic><topic>NK Cell Lectin-Like Receptor Subfamily K</topic><topic>Receptors, Immunologic - metabolism</topic><topic>Receptors, Natural Killer Cell</topic><topic>Recombinant Proteins</topic><topic>Sarcoma, Experimental - drug therapy</topic><topic>Sarcoma, Experimental - immunology</topic><topic>Sarcoma, Experimental - pathology</topic><topic>STAT1 Transcription Factor - metabolism</topic><topic>Transplantation, Isogeneic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bui, Jack D</creatorcontrib><creatorcontrib>Carayannopoulos, Leonidas N</creatorcontrib><creatorcontrib>Lanier, Lewis L</creatorcontrib><creatorcontrib>Yokoyama, Wayne M</creatorcontrib><creatorcontrib>Schreiber, Robert D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bui, Jack D</au><au>Carayannopoulos, Leonidas N</au><au>Lanier, Lewis L</au><au>Yokoyama, Wayne M</au><au>Schreiber, Robert D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors</atitle><jtitle>Journal of Immunology</jtitle><addtitle>J Immunol</addtitle><date>2006-01-15</date><risdate>2006</risdate><volume>176</volume><issue>2</issue><spage>905</spage><epage>913</epage><pages>905-913</pages><issn>0022-1767</issn><eissn>1550-6606</eissn><eissn>1365-2567</eissn><abstract>In this study, we show that IFN-gamma or IFN-alpha reduce expression of H60 on 3'-methylcholanthrene (MCA) sarcomas from 129/Sv mice. As determined by flow cytometry using either NKG2D tetramers or NKG2D ligand-specific mAb, H60 was identified as the NKG2D ligand most frequently expressed on these sarcomas, and its expression was selectively down-regulated by either IFN-gamma or IFN-alpha in a manner that was dose- and time-dependent and reversible. Down-regulation occurred at the transcript level and was STAT1-dependent. It also had functional consequences. IFN-gamma-treated MCA sarcomas with high levels of H60 were resistant to killing by IL-2-activated NK cells. Resistance was not solely dependent on enhanced MHC class I expression but rather also required H60 down-regulation. IFN-gamma-treated tumor cells also displayed diminished capacity to down-regulate NKG2D on freshly isolated NK cells. Transplanted tumor cells reisolated from immunocompetent mice displayed reduced H60 expression and increased MHC class I expression compared with tumor cells that were either left unmanipulated or reisolated from mice treated with neutralizing IFN-gamma-specific mAb. This report thus represents the first demonstration that certain cytokines and specifically the IFNs regulate expression of specific NKG2D ligands on murine tumors. This process most likely helps to specify the type of immune effector cell populations that participate in host-protective antitumor responses.</abstract><cop>United States</cop><pub>Am Assoc Immnol</pub><pmid>16393975</pmid><doi>10.4049/jimmunol.176.2.905</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-1767
ispartof Journal of Immunology, 2006-01, Vol.176 (2), p.905-913
issn 0022-1767
1550-6606
1365-2567
language eng
recordid cdi_proquest_miscellaneous_67607735
source MEDLINE; Wiley Free Content; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals; PubMed Central; Alma/SFX Local Collection
subjects Animals
Base Sequence
Cell Line, Tumor
Cell Proliferation
Cytotoxicity, Immunologic
DNA, Complementary - genetics
DNA, Neoplasm - genetics
Down-Regulation - drug effects
Histocompatibility Antigens Class I - metabolism
Humans
Interferon Type I - pharmacology
Interferon-gamma - pharmacology
Killer Cells, Natural - immunology
Ligands
Mice
Mice, Inbred C57BL
Minor Histocompatibility Antigens - genetics
Minor Histocompatibility Antigens - metabolism
Neoplasm Transplantation
NK Cell Lectin-Like Receptor Subfamily K
Receptors, Immunologic - metabolism
Receptors, Natural Killer Cell
Recombinant Proteins
Sarcoma, Experimental - drug therapy
Sarcoma, Experimental - immunology
Sarcoma, Experimental - pathology
STAT1 Transcription Factor - metabolism
Transplantation, Isogeneic
title IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A54%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IFN-Dependent%20Down-Regulation%20of%20the%20NKG2D%20Ligand%20H60%20on%20Tumors&rft.jtitle=Journal%20of%20Immunology&rft.au=Bui,%20Jack%20D&rft.date=2006-01-15&rft.volume=176&rft.issue=2&rft.spage=905&rft.epage=913&rft.pages=905-913&rft.issn=0022-1767&rft.eissn=1550-6606&rft_id=info:doi/10.4049/jimmunol.176.2.905&rft_dat=%3Cproquest_cross%3E67607735%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17464839&rft_id=info:pmid/16393975&rfr_iscdi=true